EHA 2023 | Improving eligibility for treatment-free remission in CML
Massimo Breccia
• 13 Jun 2023
Massimo Breccia, MD, Sapienza University of Rome, Rome, Italy, discusses the important goal of treatment-free remission (TFR) in chronic myeloid leukemia, commenting on strategies to increase patient eligibility for TFR, such as early tyrosine kinase inhibitor (TKI) switch, combinatorial strategies, TKI de-escalation strategies, and using novel TKIs like asciminib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria by Novartis, BMS, Incyte, Pfizer, AOP, Abbvie
